Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?

Simmons CE, Kuchuk I, Freedman OC, Colgan T, Dodd A, Kulhanek K, Sheiner J, Dranitsaris G, Dowsett M, Folkerd E, Clemons MJ.

Clin Oncol (R Coll Radiol). 2012 Oct;24(8):e128-9. doi: 10.1016/j.clon.2012.06.009. Epub 2012 Jul 12. No abstract available.

PMID:
22795828
2.

Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?

Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M.

Oncologist. 2008 Mar;13(3):222-31. doi: 10.1634/theoncologist.2007-0234. Review.

3.

Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.

Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E, Singer CF, Seifert M.

Climacteric. 2011 Jun;14(3):339-44. doi: 10.3109/13697137.2010.529967. Epub 2011 Jan 13.

PMID:
21226657
4.

Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.

Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS.

Climacteric. 2005 Mar;8(1):83-92.

PMID:
15804736
5.

Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.

Moegele M, Buchholz S, Seitz S, Ortmann O.

Arch Gynecol Obstet. 2012 May;285(5):1397-402. doi: 10.1007/s00404-011-2181-6. Epub 2012 Jan 3. Review.

PMID:
22212649
6.
7.

Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.

Kunovac Kallak T, Baumgart J, Stavreus Evers A, Sundström Poromaa I, Moby L, Kask K, Norjavaara E, Kushnir MM, Bergquist J, Nilsson K.

Climacteric. 2012 Oct;15(5):473-80. doi: 10.3109/13697137.2011.642427. Epub 2012 Feb 11.

PMID:
22324859
8.

[Vaginal oestrogen therapy in women with hormone-sensitive breast cancer].

Bak AM, Laursen BE, Rungby J, Brock B.

Ugeskr Laeger. 2011 Feb 28;173(9):648-51. Danish.

PMID:
21362392
9.

Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials.

Mazzarello S, Hutton B, Ibrahim MF, Jacobs C, Shorr R, Smith S, Ng T, Clemons M.

Breast Cancer Res Treat. 2015 Jul;152(1):1-8. doi: 10.1007/s10549-015-3434-z. Epub 2015 May 24. Review.

PMID:
26003182
10.

Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H.

Oncologist. 2011;16(4):424-31. doi: 10.1634/theoncologist.2010-0435. Epub 2011 Mar 8.

11.

Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment.

Viale PH.

Oncol Nurs Forum. 2005 Mar 5;32(2):343-53. Review.

PMID:
15759071
12.

Current overview of the management of urogenital atrophy in women with breast cancer.

Pruthi S, Simon JA, Early AP.

Breast J. 2011 Jul-Aug;17(4):403-8. doi: 10.1111/j.1524-4741.2011.01089.x. Epub 2011 Jun 6.

PMID:
21645165
13.

Update on aromatase inhibitors in breast cancer.

Gould RE, Garcia AA.

Curr Opin Obstet Gynecol. 2006 Feb;18(1):41-6. Review.

PMID:
16493259
14.

Aromatase inhibitors in breast cancer.

Hiscox S, Davies EL, Barrett-Lee P.

Maturitas. 2009 Aug 20;63(4):275-9. doi: 10.1016/j.maturitas.2009.05.008. Epub 2009 Jul 3. Review.

PMID:
19577386
15.

Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.

Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S.

Steroids. 2007 Jul;72(8):666-71. Epub 2007 May 21.

PMID:
17588628
16.

Effect and safety of 17 beta-estradiol vaginal tablet in postmenopausal women with urogenital symptoms.

Manonai J, Theppisai U, Chittacharoen A.

J Med Assoc Thai. 2001 Jul;84(7):1015-20.

PMID:
11759960
17.
18.

Managing urogenital atrophy.

Palacios S.

Maturitas. 2009 Aug 20;63(4):315-8. doi: 10.1016/j.maturitas.2009.04.009. Epub 2009 Jun 2. Review.

PMID:
19493638
19.

Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors.

Batalo M, Nagaiah G, Abraham J.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1277-82. doi: 10.1586/era.11.112. Review.

PMID:
21916581

Supplemental Content

Support Center